Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants.
about
Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsTipping the balance both ways: drug resistance and virulence in Candida glabrataCryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomesGain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulenceTranscriptional Control of Drug Resistance, Virulence and Immune System Evasion in Pathogenic Fungi: A Cross-Species ComparisonComparative lipidomics in clinical isolates of Candida albicans reveal crosstalk between mitochondria, cell wall integrity and azole resistanceProteomic analysis of cytosolic proteins associated with petite mutations in Candida glabrata.Loss of in vitro resistance in Candida glabrata following discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient.Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrataMilbemycin A4 oxime as a probe of azole transport in Candida glabrataThe role of Candida albicans homologous recombination factors Rad54 and Rdh54 in DNA damage sensitivity.Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates.UPC2A is required for high-level azole antifungal resistance in Candida glabrata.Pivotal role for a tail subunit of the RNA polymerase II mediator complex CgMed2 in azole tolerance and adherence in Candida glabrataEvaluation of reference genes for real-time quantitative PCR studies in Candida glabrata following azole treatment.Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in miceInvolvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans.Milbemycins: more than efflux inhibitors for fungal pathogensSTB5 is a negative regulator of azole resistance in Candida glabrataA fungal family of transcriptional regulators: the zinc cluster proteinsMembrane Proteome-Wide Response to the Antifungal Drug Clotrimazole in Candida glabrata: Role of the Transcription Factor CgPdr1 and the Drug:H+ Antiporters CgTpo1_1 and CgTpo1_2Evaluation of Polymorphic Locus Sequence Typing for Candida glabrata Epidemiology.Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells.Upregulation of the Adhesin Gene EPA1 Mediated by PDR1 in Candida glabrata Leads to Enhanced Host Colonization.Small chromosomes among Danish Candida glabrata isolates originated through different mechanisms.Multidrug resistance in fungiCandida glabrata drug:H+ antiporter CgQdr2 confers imidazole drug resistance, being activated by transcription factor CgPdr1.Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.Efflux-mediated antifungal drug resistance.Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence.Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.Hypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth.Flucytosine antagonism of azole activity versus Candida glabrata: role of transcription factor Pdr1 and multidrug transporter Cdr1.Coordinate control of lipid composition and drug transport activities is required for normal multidrug resistance in fungi.Membrane Proteomics Analysis of the Candida glabrata Response to 5-Flucytosine: Unveiling the Role and Regulation of the Drug Efflux Transporters CgFlr1 and CgFlr2.Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulenceAntifungal drug resistance: do molecular methods provide a way forward?Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.Retrospective observation of drug susceptibility of Candida strains in the years 1999, 2004, and 2015.Mitochondria and fungal pathogenesis: drug tolerance, virulence, and potential for antifungal therapy.
P2860
Q26863344-04E7DA5A-37DA-48A7-AA0E-87B05AF2A8CFQ26996199-178E0707-69B9-45EA-A65F-8C64B3D44179Q27315103-0A8BF1D5-1B93-4FA7-A513-819C4451CD1AQ27318203-5865449A-9477-4236-A81D-4F8E332FE44EQ28079641-39095DE0-CD43-4B42-8A3D-E16CAF10AEDBQ28480747-43CD8366-67CC-44A5-B879-A938F0B6688AQ33750421-5C2F8703-B1B4-4CA6-80A5-3FA8FD6598D7Q33797154-2BE08407-A5EE-4B04-932E-70BE34CCC239Q33847058-3DF05924-6A85-4252-BF66-D21BCDC56FD3Q34021031-9E9DB95A-462B-4AB0-92EE-3798A8C3EE70Q34032723-095CFFD7-C422-47B5-8791-E90EE4C75CFAQ34045265-15FB897F-335F-4143-A375-AD99B36DBC9AQ34058180-62863A2F-E9AC-48DE-8AE7-546D231A55AFQ34298870-857D77E7-7AA7-4CA8-9120-49DE7073289CQ34322237-0A9C82A5-1F4D-40B7-87B6-BB1433B7AB8AQ34932823-8B297853-FE96-4D47-AD42-9B4F7C869787Q35854764-FC5EAEC6-4126-4266-91A7-440E2689F804Q36558410-4D3E3779-33B4-4751-A7AA-A8DB8473E680Q36558417-F4F03767-D2DF-4DCC-A09F-492032F8066EQ36588772-63AA6528-3675-45D9-925D-53FC3FC429C1Q36604088-103B985D-5FBB-4ECF-8CFD-26453560F1E8Q36734976-590FA050-BC03-49FB-9E55-011C59CE4709Q36827007-A64D3A7D-6B2D-48AA-B328-62FE99E10D97Q36891186-AA074F29-53E7-4BBB-BC2C-C9E30D9D6B36Q36902473-B14FB8D8-BF66-484A-B374-37446EE5C8D2Q36943181-4509A63F-A3AD-4DCE-902C-065C629508E0Q36969871-15B6CD40-4ECA-4278-B458-5410B8588288Q37072109-4D31D21A-F034-432F-9B70-0D68BB94DAE7Q37156645-F093946A-79C2-4F72-BB30-D28EE2E4E60BQ37168667-4FF20B6C-CAB7-4CC5-96E0-D4D8B9052664Q37247728-5AF194BA-495B-483C-9919-D1B06AD54F52Q37247798-466B5623-8D6D-4C7E-BABD-DBE73F25613EQ37263307-63F43689-C210-43BC-8B4D-C688B4EAD06BQ37371189-F67D82DC-717F-4564-80C7-538A0A1ADA45Q37521304-A0542AA4-CDA3-4C9F-A67A-E89D29EC1CD2Q37545098-8D80D96B-7428-4284-BBD4-9BB801E748DBQ37554059-CA4ADFE6-C808-47B0-A4DB-7A4621740522Q37580801-F367CD28-AC97-43CB-9B3E-75E157B38835Q37666788-E73610D3-A3B2-4073-BF0E-0486F2FDF9C0Q37934279-4E6FF41A-7C9B-4190-92A6-1E268A807A8D
P2860
Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@ast
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@en
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@nl
type
label
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@ast
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@en
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@nl
prefLabel
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@ast
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@en
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@nl
P2093
P2860
P1476
Candida glabrata PDR1, a trans ...... l isolates and petite mutants.
@en
P2093
Anna A Krol
Huei-Fung Tsai
John E Bennett
Kelly E Sarti
P2860
P304
P356
10.1128/AAC.50.4.1384-1392.2006
P407
P577
2006-04-01T00:00:00Z